LONE TREE, Colo., Feb. 1, 2018 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the introduction of the NeuroMove device into its expanding direct sales force in the US market. The NeuroMove™ is a device designed to aid stroke survivors regain movement using the brain's ability to rewire itself, also known as "neuro-plasticity".
Thomas Sandgaard, Founder and CEO, explains: "I am excited to announce that we are re-launching the NeuroMove 900 stroke and traumatic brain injury rehabilitation product to our sales force over the next couple of months. We have for many years sold the NeuroMove device primarily to rehabilitation clinics in the US as well as internationally and while the device is designed with home use in mind we have not previously promoted it through our direct sales force. The NeuroMove 900 is a complimentary product for a large portion of our direct sales force aimed at the rehabilitation market. Stroke is the leading cause of serious, long-term disability in the United States and the NeuroMove 900 is uniquely positioned to enhance the patient's recovery. Under a newly designed marketing strategy, healthcare practitioners will be able to use the NeuroMove 900 on patients clinically and then easily transition the patient's rehabilitation to the patient's home once discharged from the clinic. Over the years, the number of rehabilitation visits allowed by insurance companies for stroke victims has decreased and the importance of products like the NeuroMove which allows patients to continue their recovery at home has increased."
Sandgaard continues: "We continue to grow our direct sales force which expands our geographic footprint across the US. This will complement our existing distribution of our flagship product, the NexWave, primarily focused on prescription strength pain relief."
For more information about the NeuroMove™ device: www.zynexneuro.com/neuromove
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel